Literature DB >> 11005552

Is adjuvant radiotherapy necessary after positive lymph node dissection in head and neck melanomas?

P Shen1, L A Wanek, D L Morton.   

Abstract

INTRODUCTION: Postoperative radiotherapy (PR) has been recommended in patients with advanced head and neck melanomas to improve regional control. This study examined the incidence of cervical recurrence among patients who did not receive PR after surgical management of node-positive head and neck melanomas.
METHODS: A computerized search of a database listing more than 10,000 patients with melanoma prospectively acquired between 1971 and 1998 identified 217 patients with pathologically positive nodes who had undergone regional lymph node dissection (RLND). Of these patients, 21 had received PR and 196 had not.
RESULTS: Median follow-up after RLND was 20 months for nonsurvivors and 32 months for survivors. The overall incidence of cervical recurrence was 14% (27/196). The 5-year cervical recurrence-free survival rate was 83%. Five-year cervical recurrence-free survival rates were 69% vs. 87% for patients with vs. without extranodal disease (P = .004), 96% vs. 81% for patients with nonpalpable vs. palpable nodes (P = .0761), and 82% vs. 91% for patients with one to three positive nodes vs. more than three positive nodes (P = .256). Multivariate analysis, which included the timing of nodal disease presentation and the effect of systemic adjuvant therapy, identified extranodal disease as the only independent predictor of cervical recurrence (P = .034). Cervical recurrence was significantly related to the subsequent occurrence of distant relapse.
CONCLUSIONS: The low incidence of cervical recurrence after RLND in patients with node-positive head and neck melanomas does not justify the routine use of PR. The only subset of patients who may benefit from PR are those with extranodal disease.

Entities:  

Mesh:

Year:  2000        PMID: 11005552     DOI: 10.1007/bf02725332

Source DB:  PubMed          Journal:  Ann Surg Oncol        ISSN: 1068-9265            Impact factor:   5.344


  10 in total

1.  Regional Radiation Therapy Impacts Outcome for Node-Positive Cutaneous Melanoma.

Authors:  Tobin Strom; Javier F Torres-Roca; Akash Parekh; Arash O Naghavi; Jimmy J Caudell; Daniel E Oliver; Jane L Messina; Nikhil I Khushalani; Jonathan S Zager; Amod Sarnaik; James J Mulé; Andy M Trotti; Steven A Eschrich; Vernon K Sondak; Louis B Harrison
Journal:  J Natl Compr Canc Netw       Date:  2017-04       Impact factor: 11.908

Review 2.  Multidisciplinary management of special melanoma situations: oligometastatic disease and bulky nodal sites.

Authors:  Amod A Sarnaik; Jonathan S Zager; Vernon K Sondak
Journal:  Curr Oncol Rep       Date:  2007-09       Impact factor: 5.075

3.  Clinicopathological Features, Staging, and Current Approaches to Treatment in High-Risk Resectable Melanoma.

Authors:  Emily Z Keung; Jeffrey E Gershenwald
Journal:  J Natl Cancer Inst       Date:  2020-09-01       Impact factor: 13.506

Review 4.  [Malignant head and neck melanoma: Part 2: Therapy].

Authors:  C Pföhler; T Vogt; C S L Müller
Journal:  HNO       Date:  2015-08       Impact factor: 1.284

Review 5.  Update on primary head and neck mucosal melanoma.

Authors:  Fernando López; Juan P Rodrigo; Antonio Cardesa; Asterios Triantafyllou; Kenneth O Devaney; William M Mendenhall; Missak Haigentz; Primož Strojan; Phillip K Pellitteri; Carol R Bradford; Ashok R Shaha; Jennifer L Hunt; Remco de Bree; Robert P Takes; Alessandra Rinaldo; Alfio Ferlito
Journal:  Head Neck       Date:  2015-05-22       Impact factor: 3.147

6.  Role of radiotherapy in melanoma management.

Authors:  Primoz Strojan
Journal:  Radiol Oncol       Date:  2010-03-18       Impact factor: 2.991

Review 7.  Melanoma: adjuvant therapy and other treatment options.

Authors:  Alicia Terando; Michael S Sabel; Vernon K Sondak
Journal:  Curr Treat Options Oncol       Date:  2003-06

8.  Adjuvant radiation therapy in metastatic lymph nodes from melanoma.

Authors:  Jean-Emmanuel Bibault; Sylvain Dewas; Xavier Mirabel; Laurent Mortier; Nicolas Penel; Luc Vanseymortier; Eric Lartigau
Journal:  Radiat Oncol       Date:  2011-02-06       Impact factor: 3.481

9.  Head and neck cutaneous melanoma: 5-year survival analysis in a Serbian university center.

Authors:  Aleksandar Višnjić; Predrag Kovačević; Asen Veličkov; Mariola Stojanović; Stefan Mladenović
Journal:  World J Surg Oncol       Date:  2020-11-29       Impact factor: 2.754

Review 10.  Early stage (I, II, III) melanoma.

Authors:  V K Sondak; M I Ross; L M Schuchter
Journal:  Curr Treat Options Oncol       Date:  2001-06
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.